ID   TK-6 [Human leukemia]
AC   CVCL_X907
SY   TK6
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473400
DR   CGH-DB; 9213-4
DR   Cosmic; 1483366
DR   DSMZ; ACC-723
DR   DSMZCellDive; ACC-723
DR   Wikidata; Q54972529
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7475285;
RX   PubMed=9737692;
RX   PubMed=10071072;
RX   PubMed=10576511;
RX   PubMed=31160637;
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Doubling time: ~60-72 hours (DSMZ=ACC-723).
CC   HLA typing: A*02:06:01,33:03:01; B*40:02:01,44:03:01; C*03:04:01;14:03 (DSMZCellDive=ACC-723).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (PubMed=10071072; PubMed=10576511; PubMed=31160637).
CC   Sequence variation: Gene fusion; HGNC; HGNC:28904; AIF1L + HGNC; HGNC:6871; MAPK1; Name(s)=MAPK1-AIF1L (PubMed=31160637).
CC   Sequence variation: Mutation; HGNC; HGNC:7545; MYB; Unexplicit; Rearranged and truncated; Zygosity=Unspecified (PubMed=9737692).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ=ACC-723
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,13
ST   D16S539: 9,12
ST   D18S51: 12,14
ST   D19S433: 13,14
ST   D21S11: 29,32.2
ST   D2S1338: 19,24
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 8,11
ST   D8S1179: 12,14
ST   FGA: 23,25
ST   Penta D: 11,12
ST   Penta E: 10,19
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 10-04-25; Version: 20
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=7475285;
RA   Watanabe T., Kataoka T., Mizuta S., Kobayashi M., Uchida T., Imai K.,
RA   Wada H., Kinoshita T., Murate T., Mizutani S., Saito H., Hotta T.;
RT   "Establishment and characterization of a novel cell line, TK-6,
RT   derived from T cell blast crisis of chronic myelogenous leukemia, with
RT   the secretion of parathyroid hormone-related protein.";
RL   Leukemia 9:1926-1934(1995).
//
RX   PubMed=9737692; DOI=10.1038/sj.leu.2401113;
RA   Tomita A., Watanabe T., Kosugi H., Ohashi H., Uchida T., Kinoshita T.,
RA   Mizutani S., Hotta T., Murate T., Seto M., Saito H.;
RT   "Truncated c-Myb expression in the human leukemia cell line TK-6.";
RL   Leukemia 12:1422-1429(1998).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=10576511; DOI=10.1016/S0145-2126(99)00131-9;
RA   Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.;
RT   "ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.";
RL   Leuk. Res. 23:1055-1060(1999).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218.1-8218.14(2019).
//